---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-002162"
form_type: "8-K"
ticker: "PMDI"
cik: "0000806517"
company_name: "PSYCHEMEDICS CORP"
filed_at: "2022-03-29T23:59:59+00:00"
generated_at: "2026-06-26T15:29:08.827086+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Psychemedics FY2021 revenue up 17% to $24.9M; net loss narrows to $0.7M from $3.9M

## Summary
- Full-year revenue $24.9M (+17% YoY); net loss $0.7M ($0.12/diluted) vs $3.9M ($0.70) loss in 2020.
- Q4 revenue $6.4M (+21% YoY) but Q4 net loss widened to $1.6M ($0.29/diluted) from $0.5M ($0.10).
- PPP loan of $2.2M forgiven; $2.6M employee retention credits recognized; $3.3M in legal settlement charges.
- Resumed quarterly dividend in Q4 2021 after pandemic suspension; board to evaluate future dividends.
- Exploring strategic alternatives; year-end cash $2.0M, working capital $4.5M, equipment debt $1.3M.

## SEC filing metadata
- accession: 0001171843-22-002162
- form_type: 8-K
- ticker: PMDI
- cik: 0000806517
- company_name: PSYCHEMEDICS CORP
- filed_at: 2022-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/806517/000117184322002162/0001171843-22-002162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/806517/000117184322002162/f8k_032922.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-002162
- JSON: https://secwatch.observer/filing/0001171843-22-002162.json
- Plain text: https://secwatch.observer/filing/0001171843-22-002162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.